TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tonix Pharmaceuticals Holding Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.73−0.31 (-5.13%)
Close on Oct 19, 2026
- Market cap
- $95.32M
- P/E (TTM)
- –
- Dividend yield
- –
Tonix Pharmaceuticals Holding Corp. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tonmya [Member] | $10.95M | $3.73M | – | – | – | – | – | – | – | – | – | – | 80.9% | – |
| Zembrace Symtouch [Member] | $2.00M | $2.93M | $3.14M | $2.58M | $1.57M | $2.03M | $2.49M | $2.49M | $1.73M | $1.85M | $3.01M | $3.29M | 14.7% | +27.1% |
| Tosymra [Member] | $594.00K | $217.00K | $833.00K | $708.00K | $428.00K | $403.00K | $95.00K | $337.00K | $481.00K | $635.00K | $767.00K | $697.00K | 4.4% | +38.8% |
By region
From the segment and revenue-disaggregation notes of Tonix Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.